Devices

DexCom Alert on Stolen Glucose Monitoring Sensors

DexCom says it has identified two lots of stolen Dexcom G7 continuous glucose monitoring sensors that were diverted into the commercial market after being designated for destruction, prompting the company to notify users and coordinate with FDA and law enforcement authorities.

The company disclosed that the affected sensors were originally classified as scrap during routine quality control processes and sent to a third-party vendor for destruction and recycling. Dexcom said the products were stolen before destruction and later sold by unauthorized third parties.

According to the company, the affected lots are Dexcom G7 sensor lots 1725204004 and 1725069002.

Dexcom said the issue was uncovered during ongoing quality and accounting reviews. The company traced sales of the stolen products to Pharmsource, LLC, which Dexcom said is not an authorized distributor of Dexcom products but supplies some independent pharmacies and durable medical equipment distributors in the U.S.

The company warned that sensors from lot 1725204004 may carry an increased risk of skin infection because the devices were not properly sterilized. Sensors from lot 1725069002 may have an increased risk of failing to provide glucose readings because of elevated internal testing failure rates, it said.

Gupta Raises Concerns About Overton’s Independence, Ideology

FDA commissioner nominee Heidi Overton’s responses on vaccines, contraception and abortion medication during her 9/24 Senate confirmation hearing raise concerns that ideology could influence her decision-making if she takes over the agency, MSNBC senior medical analyst Dr. Vin Gupta said Friday. Gupta was particularly critical of Overton’

Overton Confirmation Remains Uncertain After Senate Hearing

FDA commissioner nominee Heidi Overton emerged from her Senate confirmation hearing Thursday (see earlier story) without resolving questions about whether she has enough Republican support to advance — and with a rapidly narrowing window for confirmation before the midterm elections. The Senate Health, Education, Labor and Pensions Committee hearing provided few

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA has classified Boston Scientific's recall of its Imager II Angiographic Catheters as Class I because a manufacturing problem could cause catheter tips to degrade and detach, potentially resulting in life-threatening complications. The agency announced the Class I classification 9/25, updating an Early Alert it issued

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome

FDA has approved Roche’s Gazyva (obinutuzumab) for reducing the risk of relapse in adults and children aged 2 and older with frequently relapsing or steroid-dependent, childhood-onset idiopathic nephrotic syndrome who are in remission. The expanded approval covers the use of the CD20-directed antibody beyond its existing

Read more

Gupta Raises Concerns About Overton’s Independence, Ideology

Overton Confirmation Remains Uncertain After Senate Hearing

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome